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Abstract
Background: Foot-and-Mouth Disease Virus (FMDV) is a picornavirus that infects cloven-hoofed animals and leads to severe
losses in livestock production. In the case of an FMD outbreak, emergency vaccination requires at least 7 days to trigger an
effective immune response. There are currently no approved inhibitors for the treatment or prevention of FMDV infections.
Methodology/Principal Findings: Using a luciferase-based assay we screened a library of compounds and identified seven
novel inhibitors of 3Dpol, the RNA-dependent RNA polymerase of FMDV. The compounds inhibited specifically 3Dpol (IC50s
from 2-17 mM) and not other viral or bacterial polymerases. Enzyme kinetic studies on the inhibition mechanism by
compounds 5D9 and 7F8 showed that they are non-competitive inhibitors with respect to NTP and nucleic acid substrates.
Molecular modeling and docking studies into the 3Dpol structure revealed an inhibitor binding pocket proximal to, but
distinct from the 3Dpol catalytic site. Residues surrounding this pocket are conserved among all 60 FMDV subtypes. Site
directed mutagenesis of two residues located at either side of the pocket caused distinct resistance to the compounds,
demonstrating that they indeed bind at this site. Several compounds inhibited viral replication with 5D9 suppressing virus
production in FMDV-infected cells with EC50=12mM and EC90=20mM).
Significance: We identified several non-competitive inhibitors of FMDV 3Dpol that target a novel binding pocket, which can
be used for future structure-based drug design studies. Such studies can lead to the discovery of even more potent
antivirals that could provide alternative or supplementary options to contain future outbreaks of FMD.
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Introduction
The Foot-and-Mouth Disease Virus (FMDV) is a member of the
Aphthovirus genus in the Picornaviridae family. There are seven
known serotypes of FMDV: A, O, C, Asia 1, and Southern African
Territories (SAT) 1, 2 and 3 [1]. Within these serotypes, over 60
subtypes have also been reported. Because of this diversity there is
no universal vaccine, thus presenting challenges in the selection of
vaccine strains [2]. The most effective FMD vaccines consist of
chemically inactivated FMDV and can only offer complete
protection after seven days of vaccination because of the time
needed to trigger an immune response [3]. It has been proposed
that a combination of vaccine and antivirals can be a more
efficacious strategy to treat FMD-infected animals, contain the
spreading of the disease, and reduce the number of animals that
need to be slaughtered during outbreaks [3]. However, there are
currently no approved anti-FMDV drugs for the treatment or
prevention of FMD [4].
The FMDV genome is an 8.5kb uncapped, single-stranded
RNA. It is translated as a single polyprotein, which in turn is
cleaved into structural and non-structural proteins [5]. The non-
structural protein that carries out RNA synthesis during
transcription and replication is an RNA-dependent RNA
polymerase (RdRp or 3Dpol). Because of their pivotal roles in
the viral life cycle, viral polymerases have been a primary target
for the development of antiviral agents. In fact, there are nearly 35
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15049approved antiviral drugs that target polymerases of various
pathogens [6,7] [8,9,10,11] [12]. Thus, 3Dpol of FMDV is an
attractive target for chemotherapeutic intervention.
Among the compounds that target FMDV 3Dpol is ribavirin, a
mutagenic nucleoside analogue, known to exhibit antiviral activity
against a broad range of both DNA and RNA viruses
[13,14,15,16,17,18]. Suppression of FMDV replication in cell
cultures requires relatively high concentrations of ribavirin
(EC50=970 mM). In addition, a resistant mutation in 3Dpol
(M296I) has been shown to decrease FMDV susceptibility to
ribavirin [19,20]. Recently, another compound, 29-C-methylcyti-
dine has been shown to inhibit FMDV at low mM concentrations,
most likely through inhibition of 3Dpol [21]. Similarly, the
pyrazinecarboxamide derivative T1106 [22] has been shown to be
effective against FMDV. T1106 is converted to a triphosphate
form by host enzymes and likely inhibits the replicase activity of
FMDV 3Dpol, although the exact mechanism of FMDV
inhibition by T1106 is unknown.
Here we report the discovery of seven novel specific inhibitors of
FMDV 3Dpol, through screening of a chemical library of drug-like
compounds. We show that at least one of the compounds has the
ability to efficiently suppress viral replication without significant
cytotoxicity. Finally, we also identified the inhibitor binding site,
opening the way for structure-based drug design studies that
should help discover highly potent inhibitors of FMDV.
Results
Development of 96-well plate screening assay for the
detection of FMDV 3Dpol inhibitors
The principle of the method used in this study has been
described previously [23] and is shown in Scheme 1. Briefly, the
PPi released from the polymerase reaction is converted to ATP in
a reaction that uses adenosine 59-phosphosulfate and is catalyzed
by ATP sulfurylase. The ATP product provides the energy for the
luciferase-catalyzed conversion of D-luciferin to oxyluciferin, with
a concomitant release of photons. The sequence of reactions and
scheme is as follows:
Scheme 1.
RNA ðÞ nzNTP { { ?
3Dpol
RNA ðÞ nz1zPPi
APSzPPi { { { { { { { { ?
ATPsulfurylase
ATPzsulfate
LuciferinzATPzO2 { { { ?
Luciferase
OxyluciferinzAMPzPPizCO2
We optimized the conditions for the light-generating reaction as
described in the ‘Materials and Methods’ section. Moreover, we
improved the cost-efficiency of the overall assay by decreasing the
reagents’ concentrations of the secondary (light-producing)
reaction, while ensuring that they do not become rate-limiting
for the processing of the PPi product of the primary (polymerase)
reaction. Specifically, the concentration of ATP sulfurylase was
reduced from 300 milliUnits per assay reported elsewhere [23] to
0.03 milliUnits per assay, and at the same time the reaction
volumes were also decreased four-fold to 25 mL. To demonstrate
that under these reaction conditions the produced luminescence is
directly proportional to the amount of PPi present, we exogenously
added 1–100 mMP P i to luciferase, ATP sulfurylase and 100 mM
adenosine 59-phosphosulfate (APS) in the absence of RNA and
3Dpol. Indeed, luminescence measured within a spectral response
range of 350 nm to 650 nm was directly proportional to PPi
concentration (Figure 1A).
To validate the assay we monitored the decrease in lumines-
cence in presence of a positive control, 39-deoxy-5-methyl uridine
triphosphate (DMUT), which is a ribonucleoside analog that we
predicted would block RNA synthesis because it lacks a 39OH
group (Figure 1B). Indeed, increasing amounts of DMUT
suppressed the production of light (Figure 1B). The results from
dose response experiments were plotted using Prism 4 (GraphPad
Software Inc., CA) and an IC50 value of 0.68 mM was obtained for
DMUT at midpoint concentrations. To ensure that DMUT does
not interfere with the ATP sulfurylase and luciferase reactions we
evaluated its effect on light produced by 1 mM of exogenously
added PPi, and were able to demonstrate that varying concentra-
tions of DMUT has no effect on the production of light (data not
shown). In order to assess the quality of luciferase based assay we
also computed the Z-factor. Under our experimental conditions
the Z-factor was 0.61 which is indicative of an excellent assay
according to Zhang et al [24].
Chemical Library Screening
Using this assay we screened ,2,000 compounds from the
Maybridge HitFinder library. Representative inhibition data from
a single 96-well plate are shown in Figure 2. Typically, two to
three compounds per plate suppressed FMDV 3Dpol activity by
,90% (red bars in Figure 2A). Cumulative inhibition data are
shown in Figure 2B. Based on these results, we selected 30
compounds that suppressed luminescence $90% (red bars in
Figure 2B). These hits included compounds that inhibited the
enzymatic activity of luciferase and/or ATP sulfurylase and
consequently appeared as false positives. Therefore, to exclude
false positives we validated the compounds’ ability to specifically
suppress 3Dpol activity with fluorescently labeled primer-exten-
sion assays. Approximately 2% of the tested compounds qualified
as initial hits Most of these did not inhibit efficiently RNA synthesis
by 3Dpol, as assessed by gel-based assays. Instead, they were
shown to mostly interfere with the secondary luciferase assay
reactions (data not shown). However, seven compounds (,0.4% of
compounds tested) did inhibit RNA synthesis by 3Dpol in vitro and
were selected for further analysis. The chemical structures, the
IC50 values, and the names of these compounds are shown in
Figure 3. Two compounds, 1A8 and 3A11, had IC50s in the very
low micromolar range (,2 mM), whereas the other five (4H6, 7F8,
8C5, 9A3, 5D9) had values between 8 and 12 mM (Figures 3 and
4). Concentration-dependent analysis is shown in more detail for
three of the compounds (Figure 4).
Specificity of inhibitors
The strong suppression of 3Dpol polymerase activity by the
seven inhibitors could be due to non-specific binding of these
inhibitors to poly-rA/59-Cy3-dT18). To eliminate this possibility,
we tested inhibition of polymerase activity by other unrelated
enzymes that can use the same nucleic acid. Lack of inhibition
under such conditions, would not only prove that the inhibitors do
not block 3Dpol by binding to this T/P, but would also show that
the inhibitors block specifically the 3Dpol target, without affecting
the activity of other nucleic acid polymerases. Therefore, we tested
the ability of the inhibitors to block nucleic acid synthesis by the
DNA polymerase KF and the viral HIV-1 RT. Our results
demonstrate that at concentrations comparable to those used for
inhibition of 3Dpol (20 mM of inhibitor) the polymerase activity of
these enzymes was clearly unaffected (Figure 5A). In addition, we
monitored the effect of FMDV 3Dpol inhibitors on RNA synthesis
Inhibitors of FMDV 3Dpol
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extension pattern of GG-dinucleotide that none of the compounds
inhibited the RNA synthesis further supporting the idea that the
inhibitors are specific for FMDV 3Dpol.
Effect of inhibitors on the formation of 3Dpol-template-
primer complex
In order to study the 3Dpol inhibition mechanism in more
detail, we examined the possibility that the inhibitors affect the
nucleic acid-binding step of the RNA polymerization reaction.
Hence, we evaluated the formation of 3Dpol-T/P complex in the
presence of inhibitory concentrations of these compounds. Binding
was assessed by direct photo-chemical cross-linking of fluorescently
labeled poly-rA/59-Cy3-dT18 to 3Dpol. We have used this
technique routinely to evaluate the effect of mutations or inhibitors
on the ability of polymerases to bind nucleic acid [25,26] [27]. The
results of T/P cross-linking in presence and absence of the seven
inhibitors (Figure 6, panel A) demonstrate that the presence of
inhibitors does not significantly affect the amount of template-
primer bound to 3Dpol. Thus, inhibition of 3Dpol is not mediated
by interference with the binding of nucleic acid. Furthermore,
these data provide physical evidence that the target site for the
inhibitors is not in the T/P binding channel of 3Dpol.
Kinetic mechanism of inhibition
We selected 5D9, the compound with the most potent antiviral
activity (see below) for further kinetic characterization. We
determined the kinetic mechanism of inhibition and Ki value.
The Lineweaver–Burk plots in Figures 6B and 6C consist of a
series of at least seven lines (one for each inhibitor concentration)
intersecting at the same point on the X-axis (-1/Km) which is a
hallmark of non-competitive inhibition [28,29]. Hence, 3Dpol
inhibition by 5D9 is non-competitive with respect to both the UTP
and the nucleic acid substrates. The Ki value for 5D9 obtained
from the Dixon plot (1/V versus [5D9], not shown) was
9.462.5 mM.
Assessment of cytotoxicity
Inhibitors were evaluated for their effect on cell viability by the
XTT cell viability assay. Uninfected cells were incubated in the
presence of various doses of compounds (1, 5, 10, and 15 mM) for
24 and 48 hours. Little to no toxicity was demonstrated for all
seven compounds at the indicated concentrations (data not
shown). Cytotoxicity was also tested independently at higher
concentrations of the compounds using the CytoTox-Glo assay (1,
10, and 100 mM of inhibitors) as described by the manufacturer
(Promega, Madison, WI). Using this assay, we estimated that the
50% cytotoxic concentrations (CC50) of 5D9, 7F8, 4H6 and 9A3
were higher than 100 mM. Compounds 1A8, 8C5, and 3A11 were
more cytotoxic with CC50s of 60, 55, and 70 mM, respectively.
In vivo inhibition
We initially assessed the ability of the compounds to inhibit viral
replication post-infection of BHK-21 cells with FMDV. The
infected cells were incubated with various concentrations of the
inhibitors and at specific time points. The effect on virus growth
was assessed by plaque assay (Figure 7A and 7B). Early
experiments with multiplicity of infection (MOI) of 0.1 did not
show reproducible, significant inhibition of FMDV in the presence
of inhibitors. At an MOI value of 0.01 we observed inhibition of
viral replication by 15 mM of several compounds including 5D9,
8C5, and 1A8 (Figure 7A). In this study we focus on the most
promising inhibitor, 5D9, because it exhibited the highest,
Figure 1. Standardization of luciferase-based RNA synthesis
assay and validation using the DMUT inhibitor. (A) Light
production as a function of exogenously added pyrophosphate (PPi).
The amount of light generated by the coupled ATP sulfurylase and
luciferase reactions is directly proportional to the amount of PPi added
over a range of at least 2 logs (1–100 mM PPi). (B) Assay validation using
39-deoxy 5-methyl-uridine-59triphosphate (DMUT) as an inhibitor of
FMDV 3Dpol (DMUT lacks a 39OH required for RNA synthesis). Varying
concentrations of DMUT incubated with 1.7 mM FMDV 3Dpol, 40 nM
poly-rA/59-Cy3-dT18, and 10 mM UTP at 37 uC for one hour prior to the
addition of the ATP sulfurylase and luciferase assay components (n=3,
error bars are standard deviation from the mean).
doi:10.1371/journal.pone.0015049.g001
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after infection. Pre-treatment of BHK-21 cells with 5D9 prior to
infection with FMDV A24 Cruzeiro and subsequent challenge
with FMDV, followed by 24 hour growth in the presence of re-
administered D59, resulted in suppression of viral growth in a
dose-dependent manner and by as much as 90% at 20 mM
concentration of D59 (Figure 7B). Notably, 5D9 did not exhibit
significant cytotoxicity at these concentrations in parallel assays
using the XTT method (data not shown).
Identification of inhibitor binding site
Q-siteFinder identified 10 possible ligand-binding pockets.
Almost all of these were smaller in size than the 3Dpol inhibitors,
or were located within shallow surface crevices, very distant from
Figure 2. Relative inhibition of 3Dpol by compounds from a typical 96-well plate. (A) Relative inhibition of 3Dpol by compounds from a
typical 96-well plate. 1.7 mM FMDV 3Dpol was incubated in the presence of 20 mM compounds, 25 mM Tris-HCl, pH 7.8, 40 nM poly-rA/59-Cy3-dT18,
10 mM UTP, 25 mM KCl, and 1 mM MnCl2. After 60 minutes, ATP sulfurylase and luciferase assay components were introduced to the reactions as
described in Materials and Methods. Luminescence was measured with a 96-well plate luminometer. Data are presented as percent luminescence
inhibition (1 – [luminescence of a reaction/maximum luminescence] X 100). Red bars indicate compounds that inhibited by at least 88%. Compounds
meeting this threshold were selected for further evaluation. (B) Frequency distribution of percent luminescence. Percent luminescence was calculated
by dividing relative luminescence values of individual wells by the luminescence maximum of that plate.
doi:10.1371/journal.pone.0015049.g002
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was in close proximity to the 3Dpol active site (Figure 8A).
Docking of all seven compounds at this pocket was favorable and
with significant glide scores. Interestingly, the binding pocket is
pre-existing, and docking of the molecules required only small
adjustments to the side chains of protein residues. Hence, using the
‘induced fit docking’ protocol, which permits more structural
changes during the docking process, resulted in negligible changes
in the binding mode of the inhibitors.
The inhibitor-binding pocket is proximal to, but not overlap-
ping with the NTP binding site (Figures 8A). A close-up of the
inhibitor-binding pocket with respect to the UTP-binding site and
the possible NTP entry channel are shown in Figure 8D. The
pocket is formed by residues V55, I56, S58, K59, R168, G176,
K177, T178, R179 and I180. The energetically most favorable
binding conformers of compounds 5D9 and 1A8 docked in
FMDV 3Dpol are shown in Figures 8B and 8C, respectively. The
seven 3Dpol-inhibitors docked at the inhibitor-binding site are
shown in Figure 8E. The inhibitors appear to interact with
residues of the binding pocket through both hydrophobic and
electrostatic interactions. For example, the e-NH2 group of K59 is
shown to form hydrogen-bonds with the 5D9 and 1A8 inhibitors
(Figure 8B and 8C). Similarly, residues K177 and R168 of 3Dpol
are also within interacting distance with the inhibitors.
Validation of the inhibitor binding pocket
In order to test the hypothesis that binding at this site blocks
3Dpol polymerase activity, we generated the K59A and K177A
mutants of 3Dpol and tested their susceptibility to three inhibitors
(5D9, 1A8, and 8C5). Under the conditions tested both mutants
appeared to have polymerase activities comparable to the WT
3Dpol (Figures 9 and 10). However, results in Figures 9 clearly
demonstrate that the site-directed 3Dpol mutants are resistant to
5D9. To better quantitate the inhibition of WT and mutant
3Dpols by the inhibitors we used a filter binding assay that can be
run efficiently in a 96-well format. Results in Figure 10
demonstrate that WT is inhibited in a concentration-dependent
manner and with IC50 values of 17.4, 5.4, 14,9 mM for 1A8, 8C5
and 5D9, respectively. These values are comparable to those
determined by a gel-based assay (Figure 3). However, the activity
of K59A 3Dpol remains unchanged even at the largest
concentrations of 1A8 and 8C5 as well as 5D9, suggesting
Figure 3. Chemical structures, names, and inhibition constants of 3Dpol inhibitors. The IC50 values of 3Dpol inhibition were determined
by gel-based assays in at least four independent experiments, as described in the legend to Figure 4. Standard deviations were less than 5% in all
cases.
doi:10.1371/journal.pone.0015049.g003
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inhibitors were not readily soluble at concentrations significantly
higher than 100 mM, we were not able to accurately determine the
IC50 values of the mutant enzymes for these inhibitors.
Nonetheless, the data in Figure 10 set lower limits for resistance
of K59A to 1A8 and 8C5 (.5-fold and .20-fold, respectively).
Discussion
There are currently no FDA-approved drugs for the treatment
or prevention of FMD. Hence, control of the disease relies on
slaughter of exposed animals and vaccination with chemically
inactivated FMDV vaccines. However, these vaccines typically
provide protection against one, or few of the 60 different FMDV
subtypes. Moreover, they are unable to induce protection prior to
7 days post-vaccination. Thus, it remains important to continue
the search for cost-effective compounds that inhibit most
subtypes of FMDV. In this regard 3Dpol is a promising target
because it has an important role in viral replication and its amino
acid sequence is highly conserved among various serotypes.
Moreover, FMDV 3Dpol has been studied extensively, both
structurally and biochemically [30,31,32,33]. These studies
have provided important insights into the mechanism of RNA
synthesis by FMDV 3Dpol and have established that this enzyme
uses the same general catalytic mechanism as the polio virus
RdRp [33,34].
The synthesis of the minus strand RNA of FMDV is initiated by
uridylylation of the small FMDV protein VPg, which is
subsequently used by 3Dpol as a primer for continuing RNA
synthesis in a template-dependent manner [30,33]. Recent work
Figure 4. Gel-based validation of 3Dpol inhibition by different
compounds. Representative results depicting the dose-dependent
inhibition of RNA synthesis by 5D9, 7F8, and 8C5. RNA synthesis by
1 mM 3Dpol on 250 nM poly-rA/dT18 was carried out in the presence of
varying concentrations of compounds (0–40 mM 5D9 and 7F8, and 0–
100 mM 8C5) and 500 mM UTP in a buffer containing 50 mM Tris-HCl
pH 7.8, 60 mM KCl, 0.01% BSA, 1 mM DTT and 0.1% NP40. Lanes
labeled as P contain only free dT18 primer. To calculate the IC50, the
amount of extended dT18 primer was plotted against the varying
concentration of hits. The data points were fit to dose-response curves
by GraphPad Prizm 4.0 (experiments were repeated at least 4 times).
doi:10.1371/journal.pone.0015049.g004
Figure 5. Effect of compounds on enzymatic activity of Klenow fragment and HIV reverse transcriptase. 10 nM KF or 20 nM HIV-1 RT
were incubated with 250 nM poly-rA/dT18 and 20 mM of a 3Dpol inhibitor (1A8, 4H6, 6B11, 5D9, 7F8, 8C5, or 9A3) in a buffer containing 50 mM Tris-
HCl, pH 7.8, 60 mM KCl, 1 mM DTT, 0.01% BSA, 0.1% NP40, and 4% DMSO. DNA synthesis was initiated by the addition of 1 mM MnCl2 and 500 mM
dTTP final concentrations. No significant inhibition of KF or HIV RT is observed under these conditions. Panel B shows the RNA synthesis by BVDV
3Dpol in presence of 40 mM of each of the compounds. The RNA synthesis by BVDV 3Dpol was primed by GG dinucleotide in 50 mM Tris-HCl pH 7.8,
pH 7.8, 60 mM KCl, 1 mM DTT, 0.01% BSA, 1 mM MnCl2, 100 mM ATP, GTP, CTP and 10 mM UTP mixed with 5 mCi of a-32P-UTP. The extension of GG
can be seen as the radiolabeled bands where UTP is supposed to be incorporated.
doi:10.1371/journal.pone.0015049.g005
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initiation or elongation steps of RNA synthesis. For example, Goris
et al. [21] demonstrated that 29-C-methylcytidine inhibits RNA
synthesis of FMDV RNA [21]. Related analogs of this inhibitor
have been reported to be incorporated into nascent RNA by the
RdRp of HCV (NS5B), leading to chain termination [35–36].
Agudo et al. [14] recently demonstrated that 5-fluorouridine
triphosphate, a nucleotide analog used in cancer therapy, has a
dual (inhibitory and mutagenic) effect on FMDV RNA synthesis.
This compound was also shown to compete with UTP for covalent
binding to VPg. In a recent study, Furata et al. have proposed that
nucleoside analog T1106 suppresses FMDV replication through
inhibition of FMDV RdRp by an unknown mechanism [22].
Another study demonstrated that RNA aptamers specific to 3Dpol
inhibit efficiently the RdRp activity of the enzyme in vitro [37].
However, aptamers are highly charged oligonucleotide molecules
that may be limited by low bioavailability, and difficulty to deliver
to intracellular targets. Finally, ribavirin, a mutagenic nucleotide
analog that has been approved for the treatment of HCV
infections, has also been reported to have antiviral activity against
Figure 6. Inhibition of 3Dpol by inhibitors is non-competitive with respect to RNA and NTPs. (A) Effect of inhibitors on binding of 3Dpol
to template-primer (T/P). Binding of 3Dpol to fluorescently labeled T/P (T/P*) was assessed by determining the amount of 3Dpol-T/P* covalent
complex formed by UV-mediated cross-linking in the presence of 20 mM of inhibitors. For these experiments, 2 mg 3Dpol was incubated with 100 nM
T/P (poly-rA/59-Cy3-dT18) in a buffer containing 50 mM Tris-HCl pH 7.8, 1 mM DTT and 5 mM MgCl2 at 4uC for 10 minutes. Cross-linking was carried
out by exposing the mixture to UV for 3 minutes as described in Materials and Methods. The radiograph at the top shows equivalent amounts of
3Dpol-T/P adduct in the absence and presence of the inhibitors. The middle and bottom figures in panel A show that the amounts of poly-rA/59-Cy3-
dT18 and protein, respectively are the same in all cross-linking experiments. (B) and (C) Non-competitive inhibition profile of FMDV 3Dpol by 5D9
under steady state conditions. Kinetic experiments with 3Dpol (1 mg/0.1 ml reaction volume) were conducted in 96-well plates using the luciferase-
based assay (see methods) in the presence of increasing concentrations of 5D9 (0 to 32 mM), varying either UTP substrate (1.6-102.4 mM) (panel B) or
poly-rA/dT18 (0.1 to 6.4 mM) (panel C). In both cases the X-axis intercepts (-1/Km for the UTP or poly-rA/dT18 substrates) are not affected by the
inhibitor concentrations, which is the hallmark of non-competitive inhibition. Indicated values are the means from at least three independent
experiments.
doi:10.1371/journal.pone.0015049.g006
Inhibitors of FMDV 3Dpol
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(M296I) resulted in decreased capacity of the FMDV enzyme to
use ribavirin triphosphate as a substrate in the place of GTP and
ATP [19]. These examples illustrate the increasing importance
and challenges of targeting 3Dpol of FMDV.
In this study we screened a chemical library of small molecules
for inhibitory activity against 3Dpol. This chemical library
contains compounds that follow Lipinski’s rule of five, an empirical
rule that is used to evaluate ‘‘drug-likeness’’ and potential for oral
bioavailability in humans [38]. To identify potential inhibitors, we
used a non-radioactive assay to monitor the RdRp activity of
3Dpol by measuring the release of pyrophosphate (PPi) generated
during synthesis of the nascent RNA strand [23]. The coupled-
enzyme assay used ATP sulfurylase and firefly luciferase enzymes
to generate luminescence, proportional to the concentration of
pyrophosphate. This assay enabled initial selection of compounds
that suppressed luminescence. Compound hits were validated in a
primer extension assay (Figure 4). Some of the initial hits were false
positives, as they turned out to be inhibitors of either ATP
sulfurylase and/or firefly luciferase. This was confirmed by their
ability to suppress luminescence generated by exogenously added
PPi rather than from PPi generated from RdRp reaction. One
early concern was that the inhibitors might block polymerases
non-specifically, by binding to the minor groove of the nucleic acid
substrate. This possibility was eliminated by demonstrating that
the inhibitors did not affect the polymerase activity of two
unrelated polymerases, HIV RT and KF, using the same nucleic
acid as substrate (poly-rA/dT18).
Seven 3Dpol inhibitors were tested at the Plum Island Animal
Disease Center for in vivo (cell culture) FMDV inhibitory effects.
Their antiviral properties were evaluated using FMDV subtype
A24 Cruzeiro. Given the high homology of FMDV 3Dpol among
different serotypes it is likely that the compounds will have
antiviral activity for other FMDV serotypes as well. The cell-based
assays indicated that 5D9 had the most pronounced and consistent
antiviral effect (EC50 =12mM, EC9 =20mM). Further cytotox-
icity measurements indicated that the CC50 for 5D9 was higher
than 100 mM. Since the antiviral activity of the compound is
12 mM, the therapeutic index (CC50/EC50) is larger than 8. We
are currently evaluating analogs of the original hits to identify
compounds with improved antiviral properties. Nonetheless, the
antiviral potency of 5D9 is ,80 fold better than that of ribavirin
(EC50=970 mM, EC90=1697 mM), and comparable to 29-C-
methylcytidine (EC50=10mM, EC90=15mM) [21].
5D9 is a good candidate for use in combination with
compounds that inhibit the virus through different strategies,
including peptide-conjugated morpholino oligomers that target the
59 and 39 untranslated regions (UTRs) of the FMDV genome [31].
In addition to identifying novel FMDV inhibitors, we also
demonstrated that their mechanism of action involves targeting a
previously unidentified inhibitor binding pocket. We took
advantage of the multiple crystal structures of FMDV 3Dpol that
have been solved by the Verdaguer and Domingo groups
[20,32,39,40]. These structures represent various reaction inter-
mediates and provide key information on understanding the
molecular details of RNA-dependent RNA polymerization. We
used molecular modeling tools to search for possible binding sites
in the 3Dpol structures. We identified a site where all compounds
could be docked efficiently (Figure 8E). The binding site is pre-
existing, and efficient docking of the compounds does not require
significant conformational changes in side-chain or main-chain
atoms. Moreover, the binding pocket is highly conserved in several
crystal structures of various complexes, including: 1) the 3Dpol
structure containing template-primer, incoming UTP and released
PPi (PDB code 2E9Z), 2) the structure of unliganded 3Dpol (PDB
code 1U09), 3) the structure of RNA-bound binary complex (PDB
code 1WNE), 4) uridylylated VPg-bound complex (PDB code
2F8E), 5) the structure of 3Dpol complexed with RNA template-
primer and ATP (PDB file 2EC0), 6) 3Dpol complexed with RNA
template-primer, ATP and UTP (PDB code 2E9Z), 7) 3Dpol
complexed with template-primer RNA and 5F-UTP (PDB code
2E9T) and 8) 3Dpol complexed with template-primer RNA and
ribavirin (PDB code 2E9R). Hence, the molecular modeling
studies predicted that the inhibitors can bind to multiple
intermediates of the enzymatic reaction, as expected from non-
competitive inhibitors. This prediction is consistent with our
Figure 7. Inhibition of FMDV in cell-based assays. (A) Evaluation
of anti-FMDV activity of 3Dpol inhibitors. Treatment with 15 mMo f
various compounds was performed following virus adsorption on BHK-
21. The cells were further incubated in the presence of compound for
another 24 hours and virus titer was determined by plaque assays
(PFUs, plaque forming units) as described in the Materials and Methods.
Experiments were done in duplicates. (B) Dose–dependence of FMDV
inhibition by 5D9. Compound 5D9 was administered to BHK-21 cells in
a dose-dependent manner prior to infection with FMDV. Post-infection,
the compound was re-administered and incubated for another
24 hours. Following this incubation, samples were taken and plaque
assays were performed. Results are reported as percent inhibition
compared to a sample without inhibitor, and demonstrate a dose-
dependent inhibition of virus replication. At the highest concentrations
of 5D9 (20 mM) there was a greater than 90% inhibition of virus
replication. Error bars represent standard error of the mean for two
experiments. At these inhibitor concentrations no decrease in cell
viability was observed.
doi:10.1371/journal.pone.0015049.g007
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by 5D9 and 7F8 is indeed non-competitive. Detailed analysis of
the mechanism of inhibition and resistance of all seven inhibitors
will be published elsewhere. Importantly, residues that line the
inhibitor-binding pocket are entirely conserved among all 60
FMDV subtypes. Hence, we expect that unlike vaccines that are
subtype-specific, small molecule inhibitors that target this pocket
can have broad antiviral properties.
The inhibitor binding pocket is proximal to, but distinct from,
the NTP binding site of 3Dpol (Figures 8A and 8D). The
compounds are expected to bind in a channel that may be used for
entry of the nucleotide substrates and exit of the PPi product
(Figure 8D) [32]. Interestingly, the non-competitive type of
inhibition is reminiscent of the mechanism by which non-
nucleoside reverse transcriptase inhibitors (NNRTIs) block the
DNA polymerase activity of HIV RT [41], [11,42,43], or other
non-nucleoside inhibitors that inhibit the RNA polymerase NS5B
of Hepatitis C Virus [44] [28] [45,46,47,48]. The molecular
details of the inhibition and resistance mechanism will be
elucidated by ongoing pre-steady state kinetic and crystallographic
studies. Such studies should also facilitate structure-based drug
design of more potent antivirals that target 3Dpol. The highly
conserved inhibitor-binding pocket will provide numerous oppor-
tunities for hydrophobic interactions between the aromatic/
hydrophobic ring systems of the inhibitors and the hydrophobic
residues the line the pocket (V55, I56, and I180, or the aliphatic
chains of residues K59, K177, R168, R179) or hydrogen-bond or
hydrophilic interactions between the inhibitors and the e-NH2 of
K59, K177, or the guanidinium groups of R168 and R179.
It is noteworthy that two of the seven inhibitors, 5D9 and 7F8,
contain sulfonamide or sulfone chemical groups. Similar com-
pounds have long been used for the treatment of bacterial, viral
and other infections [49]. Hence, we are currently performing
structure-activity studies to improve the potency of these
inhibitors.
In conclusion, our study demonstrates that we have identified a
pocket in 3Dpol that can be targeted by inhibitors that block RNA
synthesis through a non-competitive inhibition mechanism. These
compounds can have antiviral properties and could be used for
blocking FMDV replication. Further studies may lead to the
development of even more potent small molecule inhibitors of
FMDV that can be used as vaccine-alternatives and/or offer
Figure 8. Poses of inhibitors docked at the inhibitor binding pocket of 3Dpol. Panel A shows a surface representation of the complex of
3Dpol (yellow) with RNA (gray ribbons for template and primer) and UTP (only the gamma phosphate of UTP is seen) (PDB code 2E9Z). The inhibitor
binding site is shown in orange, proximal to the UTP binding site. Panels B and C show close-ups of the molecular surface areas of 5D9 (magenta) and
1A8 (green), respectively, docked at the inhibitor binding site of 3Dpol. Potential hydrogen bond interactions that involve the e-NH2 of K59 and the
inhibitors are indicated with yellow dotted lines. Some 3Dpol side chains have been removed for clarity. Panel D shows the position of the inhibitor
binding pocket with respect to UTP with 1A8 docked at the inhibitor binding site. The potential NTP entry channel of 3Dpol is indicated with a yellow
arrow. Atom types are displayed as: C, white; O, red; N, blue; S, yellow, P orange, and Cl, green. Panel E shows all inhibitors docked at the inhibitor
binding pocket (1A8 in violet, 3A11 in blue, 4H6 in cyan, 5D9 in green, 7F8 in yellow, 8C5 in orange, and 9A3 in red), proximal to the UTP binding site.
doi:10.1371/journal.pone.0015049.g008
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The Maybridge-Hitfinder chemical library of compounds
(version 6) was purchased from Maybridge, (Thermo Fisher
Scientific, Cornwall, United Kingdom). Screening reactions were
carried out in Microfluor 2 black U-bottom 96-well plates (Fisher
Scientific). Oligonucleotides were purchased from Fermentas,
(Glen Burnie, Maryland). Ultrapure nucleotides were purchased
from Novagen (Madison, Wisconsin) and 39-deoxy 5-methyl-
uridine 59-triphosphate (DMUT) was obtained from TriLink
BioTech (San Diego, CA). Compound hits were also purchased
independently from Ryan Scientific Inc. (Mt. Pleasant, SC) for
independent validation of the inhibition results.
Expression and purification of WT, K59A and K177A
FMDV 3Dpol
Plasmid pET-28a containing the FMDV 3Dpol coding
sequence with an AAALE linker at the carboxyl terminus followed
by 6 histidines was obtained from Drs. Verdaguer and Domingo
[32]. It was transformed into the Rosetta 2 expression strain
(Novagen). Kanamycin-resistant colonies were grown at 37uC and
induced at A600 of 0.9–1.0 by the addition of 1 mM isopropyl b-D-
1-thiogalactopyranoside (IPTG). The cells were harvested by
centrifugation (4,500 g, 20 min) and stored at -20uC. Frozen cell
pellets were resuspended in buffer A (25 mM Tris-HCl pH 8.0,
500 mM NaCl and 5% glycerol). The protein was purified by
nickel-affinity chromatography with a gradient of 25 mM to
500 mM imidazole in buffer A. Fractions containing pure protein
(,95%) were pooled and dialyzed against the storage buffer
containing 12.5 mM Tris-HCl pH 8.0, 100 mM NaCl and 50%
glycerol. The protein concentration was determined using a
Nanodrop spectrophotometer (Thermo Scientific, Wilmington,
DE) and confirmed by comparison to known amounts of
coomassie-stained Bovine Serum Albumin.
The K59A and K177A mutants were prepared using the
Stratagene QuikChange site-directed mutagenesis kit as described
by the manufacturer, and expressed and purified as described
above for the WT enzyme.
96-well plate screening assay
The Maybridge-Hitfinder library of compounds was screened
using a luciferase-based assay similar to the one developed by
Lahser and Malcolm [23], which quantitates the pyrophosphate
(PPi) product of nucleic acid synthesis. The chemical library was
supplied as lyophilized films in a 96-well plate format. We used a
Precision Microplate Pipetting system (Winooski, VT) to suspend
the compounds in 100% dimethyl sulfoxide (DMSO) to a final
concentration of 10 mM (‘mother plates’). From these plates
several sets of ‘daughter plates’ containing 500 mM of each
compound (in 100% DMSO) were generated and stored at
280uC.
The polymerase reactions that generate pyrophosphate product
were carried out in a 96-well format. Specifically, each well
contained 25 ml of reaction mixture containing 25 mM Tris-HCl,
pH 7.8, 25 mM KCl, 1.7 mM 3Dpol, 10 mM UTP, 1 mM MnCl2
and 20 mM inhibitor. The polymerase reaction was initiated by the
addition of 40 nM of poly-rA/dT18. The reactions were allowed to
proceed for 1 hour at 37uC followed by 10 minutes incubation on
ice. The released pyrophosphate (PPi) from the polymerase
reaction was subsequently quantitated by adding to the above
polymerase reaction mixture a luciferase reaction mixture (25 ml)
containing 4.8 nM luciferase, 6610
25 units of adenosine-59-
triphosphate sulfurylase (ATPsulfurylase) (Sigma Aldrich, St. Louis,
MO), 5 mM adenosine-59-phosphosulfate (APS), 310 mMd -
luciferin, 0.5 mM coenzyme-A, 25 mM Tris-HCl pH 7.5, and
50 mM NaCl. Luminescence was measured immediately with a
Veritas microplate luminometer (Turner BioSystems Sunnyvale,
CA).
Gel-based primer extension assay for validation of
inhibitors
Compounds that suppressed production of light during the
screening of the library were validated directly by measuring their
ability to inhibit the RNA-dependent RNA polymerase activity of
3Dpol in gel-based primer extension assay, as we have done
previously [50], and using optimized conditions stated below. All
concentrations represent the final concentrations in the reactions
unless otherwise indicated. The RNA synthesis by 1 mM 3Dpol
using 250 nM fluorescently labeled poly-rA/59-Cy3-dT18 was
carried out in the presence of varying concentrations of inhibitors
(0–40 mM or 0–100 mM) and 500 mM UTP in a buffer containing
50 mM Tris-HCl pH 7.8, 60 mM KCl, 0.01% BSA, 1 mM DTT
and 0.1% NP40. The compounds were dissolved in DMSO, and
the final concentration of DMSO in the reactions (including the
controls) was 4%. Reactions were initiated by the addition of
MnCl2 to a final concentration of 1 mM, and allowed to proceed
for 1 hour at 37uC before quenching with 95% formamide.
Inhibition of RNA polymerization was monitored by resolving the
primer extension products on 16% polyacrylamide-8 M urea gels,
followed by scanning of gels on a Fuji FLA-5000 Fluorometer.
Bands corresponding to full extension products were quantified
using the Fujifilm MultiGauge software (Stamford, CT). IC50s
were obtained from dose-response curves using GraphPad Prism
Figure 9. Susceptibility of WT and 3Dpol mutant enzymes to a
3Dpol inhibitor. Gel-based assays were used to evaluate the effect of
K59A and K177A mutations on the susceptibility of 3Dpol to 5D9.
Representative results depicting the dose-dependent inhibition of RNA
synthesis by 3Dpol in presence of 5D9 are shown in this figure. RNA
synthesis by 1 mM 3Dpol, 500 mM UTP, and 250 nM poly-rA/dT18 in a
buffer containing 50 mM Tris-HCl pH 7.8, 60 mM KCl, 0.01% BSA, 1 mM
DTT and 0.1% NP40 was carried out for 1 hour in the presence of
varying concentrations of inhibitors (0–100 mM) and 500 mM UTP.
doi:10.1371/journal.pone.0015049.g009
Inhibitors of FMDV 3Dpol
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e150494. All inhibition experiments were performed independently at
least three times.
Filter binding assay for assessment of the susceptibility
of the K59A or K177A 3Dpol mutants to the inhibitors
The effect of mutations on the susceptibility of 3Dpol to various
compounds was assessed using two assays. First, by a gel-based
primer extension assay described above, and second, by a 96-well
plate filter binding assay. The latter assay allowed fast and
accurate calculation of IC50s by measuring the incorporation of
32P-UMP by the WT and mutant 3Dpols into poly-rA/dT18
template-primer (T/P), in the presence and absence of inhibitors.
Assays were carried out in a final volume of 20 ml containing 1 mM
enzyme and 50 mM Tris-Cl pH 7.8, 1 mM DTT, 0.01% BSA,
0.1% NP40, 60 mM KCl, 250 nM unlabeled poly-rA/dT18 and
varying concentrations (0–100 mM) of inhibitors. Reactions were
Figure 10. Filter binding assay to estimate the IC50 of 3Dpol inhibitors. 250 nM poly-rA/dT18 was incubated with 1 mM 3Dpol in 50 mM Tris-
HCl pH 7.8, 60 mM KCl, 0.01% BSA, 1 mM DTT and 0.1% NP40 in presence of varying amounts of inhibitors (0–100 mM) (shown are representative
results for 1A8, 8C5, and 5D9). Reactions were initiated by the addition of 1 mM MnCl2, 100 mM UTP (final concentration), and 0.125 mCi of a-
32P-UTP
per reaction. The reactions were allowed to proceed for one hour before quenching with 50 mM EDTA. Products were filtered through a charged
nylon filter using a vacuum manifold apparatus (Whatman-GE Healthcare, Piscataway, NJ). The amount of radioactive material was quantitated by
densitometery and plotted against the concentration of inhibitors. The data were fit to dose response curves using GraphPad Prism 4 to determine
the IC50s.
doi:10.1371/journal.pone.0015049.g010
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32P-labeled UTP
(0.5 mCi/nmol) and 1 mM MnCl2 (final concentrations). After
incubation at room temperature for 1 hour, the reactions were
terminated by the addition of 50 mM EDTA. The reaction
products were then passed through a positively charged nylon
membrane using a vacuum manifold apparatus (Whatman-GE
Healthcare, Piscataway, NJ). Extended primers that had been
radiolabeled by the incorporation of a-
32P-UMP were bound to
the filter, whereas the unincorporated a-
32P-UTP was filtered
through the membrane. Radioactive filters were exposed to
phosphor screens followed by phosphorimaging and analyzed
using the Multi Gauge V3.0 software (FujiFilm). Dose response
curves were plotted using GraphPad Prism 4 to determine the
IC50s.
Specificity of inhibitors for FMDV 3Dpol
To establish that the compounds did not inhibit the 3Dpol
activity by merely chelating with the nucleic acid, we monitored
the effect of 20 mM of the inhibitors on the DNA synthesis by two
unrelated nucleic acid polymerases, using the same template-
primer system (poly-rA/dT18). Hence, we measured DNA
synthesis by 10 nM of the Klenow Fragment (KF) of E. coli
DNA polymerase I or 20 nM of the HIV-1 reverse transcriptase
(HIV-1 RT), using 250 nM fluorescently labeled poly-rA/59-Cy3-
dT18 (37uC for 1 hour), in 50 mM Tris-HCl, pH 7.8, 60 mM
KCl, 1 mM DTT, 0.01% BSA, 1 mM MnCl2 and 500 mM
dTTP. All reactions, including controls or in the presence of
inhibitors, contained 4% DMSO.
In addition to assessing the DNA synthesis by KF and HIV-1
RT, we also tested the ability of compounds to inhibit the RNA
synthesis by Bovine Virus Diarrhea Virus RNA polymerase
(NS5B). The RNA synthesis in absence and presence of 40 mM
compounds was carried out in a buffer containing 50 mM Tris-
HCl pH 7.8, pH 7.8, 60 mM KCl, 1 mM DTT, 0.01% BSA,
1 mM MnCl2, 100 mM ATP, GTP, CTP and 10 mM UTP mixed
with 5 mCi of a-32P-UTP. The incorporation by 1 mM NS5B was
monitored on 1 mM 31-mer template (59-CCAUAGAUAG-
CAUUGGUGCUCGAACAGUGAC-39) using GG as the prim-
ing sequence.
Effect of inhibitors on the ability of 3Dpol to bind nucleic
acid
To assess if the inhibitors interfere with the binding of nucleic
acid by 3dpol, we used UV-mediated cross-linking of template-
primer to 3Dpol in the presence of the inhibitors. For UV-
mediated cross-linking, 2 mg enzyme were incubated with 100 nM
of fluorescently labeled poly-rA/59-Cy3-dT18 in a buffer contain-
ing 50 mM Tris-HCl pH 7.8, 1 mM DTT and 5 mM MgCl2 at
4uC, for 10 minutes. The samples were exposed to UV light
(254 nm) at a dose rate of 125 mJ/cm
2 for 3 min using a BioRad
GS Gene Linker UV chamber (BioRad Laboratories, CA), as
described previously [25,26] [27]. Measurement of covalent
attachment of labeled poly-rA/59-Cy3-dT18 to enzyme was
assessed by 8% SDS-polyacrylamide gel electrophoresis. Bands
corresponding to 3Dpol cross-linked to template-primer were
visualized by a Fuji FLA-5000 phosphorimager and quantified
using FujiFilm MultiGauge (Stamford, CT).
Enzyme kinetics
To determine the inhibition mode with respect to UTP
(competitive or non-competitive), we used the 96-well luciferase–
based assay to measure the effect of 5D9 in the RdRp activity of
3Dpol. 25 ml reactions containing 200 nM 3Dpol, 25 mM Tris-
HCl, pH 7.8, 50 mM KCl, 1 mM MnCl2 and varying 5D9 (0–
32 mM) were initiated by adding 4 mM poly-rA/dT18. These
reactions also included increasing amounts of UTP (1.6–
102.4 mM). For determining the inhibition mode with respect to
nucleic acid, the poly-rA/dT18 concentration was varied (from 0.1
to 6.4 mM) in the presence of 50 mM UTP and increasing amounts
of 5D9 (from 0–128 mM). The reactions were allowed to proceed
for 30 minutes at 37uC, followed by 10 minutes incubation on ice.
Released PPi was quantitated as described above for the 96-well
plate screening assay. Assays were carried out in three indepen-
dent experiments. Results were analyzed in Lineweaver–Burk
graphs (1/V vs. 1/[S] for various inhibitor concentrations) using
GraphPad Prism. Dixon plots (1/V vs. [5D9]) were used to
determine the inhibitor Ki from the X-axis intercept [51].
Assessment of cytotoxicity
We assessed the effect of the inhibitors on cellular viability using
a commercially available kit (Roche Diagnostics, Indianapolis, IN)
that measures metabolization of XTT 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hy-
droxide). XTT is a tetrazolium salt that is reduced to a soluble
orange-colored formazan product by mitochondrial succinate
dehydrogenase, which retains activity in metabolically active cells.
The amount of this product is proportional to the number of living
cells and can be spectrophotometrically quantified. The assay was
performed in triplicates as follows: Baby hamster kidney (BHK-21)
cells (American Type Culture Collection, Manassas, VA) were
seeded to 90% confluency in a 96-well plate. Cells were incubated
for 24 hours with 1, 5, 10, and 20 mM of inhibitors in a final
volume of 100 mL phosphate buffered saline (PBS). Cells treated
with Triton X-100 were used as a control for loss of cell viability.
After the 24-hour incubation period the PBS was removed and
replaced with phenol red-free media. 20 mL of XTT was added
per well and cells were incubated for an additional 3.5 hours. After
incubation, the optical density at 450 nm was read by a plate
reader. We also assessed the cytotoxic effect of the inhibitors
independently using the CytoTox-Glo kit (Promega, Wisconsin),
which measures cleavage of a luminogenic AAF-Glo substrate by
dead-cell proteases. Assays were carried out as described by the
manufacturer [52]. Following cleavage, a substrate for luciferase
(aminoluciferin) was released, resulting in the luciferase-mediated
production of light. Percent of dead cells were determined in the
presence of inhibitor concentrations up to 100 mM.
In vivo assessment of inhibition
For the initial assessment of the antiviral compounds (Figure 7A),
BHK-21 cells were grown in BME BHK-21 medium supplement-
ed with 10% bovine calf serum. BHK-21 cells were seeded
(150,000 per well) in a 24-well plate in antibiotic-free media. They
were subsequently infected with 0.01 multiplicity of infection
(MOI) of FMDV A24 Cruzeiro and incubated for1 hr at 37uCt o
allow for virus adsorption. Subsequently, the cells were treated
with ice-cold 2-morpholinoethanesulfonic acid (MES)-buffered
saline (25 mM MES pH 5.5, 145 mM NaCl) to inactivate residual
virus particles and then rinsed twice with minimal essential media
(MEM) (Invitrogen, Carlsbad, CA) containing 1% fetal bovine
serum (FBS) and 25 mM HEPES (pH 7.4). Inhibitors were added
to the infected cells and cells were further incubated at 37uC for
24 hours. At this time, plates were frozen for subsequent
determination of virus titers. These were determined by plaque
assays using a 1% gum tragacanth overlay, and the mixture was
incubated for 24 h at 37uC. The plates were fixed and stained for
analysis with crystal violet, 0.3% in HistoChoice (AMRESCO,
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[31].
The experiments on characterization of 5D9 (Figure 7B) were
carried out as follows: 5D9 was added in a dose-dependent
manner to BHK-21 cells and incubated for one hour to allow for
absorption of the inhibitor. Cells were washed prior to infection to
remove any residual DMSO, which could potentially modify virus
adsorption. Subsequently, cells were infected by adding FMDV
A24 Cruzeiro (MOI of 0.01) and incubated for 1 hour at 37uCt o
allow for virus adsorption. After washing and neutralizing the cells
as described above, 5D9 was re-administered in a dose-dependent
manner and the infected cells were further incubated with the
inhibitor for 24 hours at 37uC. At this time, plates were frozen and
plaque analysis was carried out as described above. Assays were
performed in triplicate and included controls with DMSO (0.5%
in media) and no inhibitor.
Search for potential inhibitor binding sites
We used the crystal structure coordinates of the FMDV 3Dpol
complex with RNA, UTP and PPi (PDB file 2E9Z) to search for
potential binding sites of the inhibitors, using the Q-siteFinder
program [53]. The potential inhibitor binding sites were initially
evaluated by size (if they were large enough to allow docking of the
inhibitors. For those sites that were of the right size we performed
additional docking studies of the various inhibitors. For this
purpose we generated molecular models of the compounds based
on structure data files (sdf) using LigPrep, a ligand preparation tool
that is interfaced with Maestro (Schrodinger Inc. NY). The
structures generated by LigPrep were docked into the ternary
complex of FMDV 3Dpol with RNA and UTP (PDB file 2E9Z)
using the software ‘Glide’ with extra precision (XP) and ‘Induced
Fit Docking’ workflow incorporated in Maestro (Schrodinger Inc.
NY).
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